Great news! The inhalation solution of ipratropium bromide (2ml:0.25mg and 2ml:0.5mg), independently developed by Nanjing Leecan, has recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration (NMPA), with drug approval numbers: National Drug Approval No. H20255526 and National Drug Approval No. H20255525.
.png "/uploads/image/2025/10/11/图片1(1).png")
This marks another milestone for Leecan in the field of respiratory disease treatment, signifying another solid step forward in the development and production of high-end inhalation formulations. It also brings more and better treatment options for patients suffering from chronic obstructive pulmonary disease (COPD), asthma, and other respiratory diseases!
The approved dual-specification product further enriches and strengthens the product matrix of Leecan in the field of inhalation formulations, once again demonstrating the company's formidable capabilities and exceptional standards in drug R&D, quality control, and manufacturing processes. This achievement is also inseparable from the unwavering support and sincere collaboration of our partners. On this occasion, we would like to express our deepest gratitude to all colleagues who have worked diligently on this project, as well as to the friends who have long cared for and supported the development of Leecan!
The acquisition of the drug manufacturing license marks not only a triumphant conclusion but also a brand-new beginning. Moving forward, Leecan will strictly adhere to the approved manufacturing processes and management protocols for commercial production of this product. Every stage of production and every detail will undergo the most rigorous quality control measures, ensuring consistent and stable quality of each batch of marketed products. We strive to bring this high-quality medication to medical professionals and patients nationwide as soon as possible, contributing Leecan's strength to the cause of respiratory health!
025-58181716
Share:
